These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35709444)

  • 1. Searching for an Alternate Anticoagulant for Cardiopulmonary Bypass: Does Two Plus Two Equal Two?
    Sniecinski RM; Nielsen VG; Tanaka K
    Anesth Analg; 2022 Jul; 135(1):49-51. PubMed ID: 35709444
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery.
    Koza MJ; Messmore HL; Wallock ME; Walenga JM; Pifarre R
    Thromb Res; 1993 Apr; 70(1):67-76. PubMed ID: 8390111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiopulmonary Bypass Without Heparin.
    Rehfeldt KH; Barbara DW
    Semin Cardiothorac Vasc Anesth; 2016 Mar; 20(1):40-51. PubMed ID: 26872706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.
    Spanier TB; Oz MC; Minanov OP; Simantov R; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 May; 115(5):1179-88. PubMed ID: 9605089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Con: heparin is not the best anticoagulant for cardiopulmonary bypass.
    Fitch JC
    J Cardiothorac Vasc Anesth; 1996 Oct; 10(6):819-21. PubMed ID: 8910167
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiopulmonary bypass in humans: bypassing unfractionated heparin.
    Frederiksen JW
    Ann Thorac Surg; 2000 Oct; 70(4):1434-43. PubMed ID: 11081925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
    Dyke CM; Smedira NG; Koster A; Aronson S; McCarthy HL; Kirshner R; Lincoff AM; Spiess BD
    J Thorac Cardiovasc Surg; 2006 Mar; 131(3):533-9. PubMed ID: 16515902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anticoagulant therapy and cardiopulmonary bypass].
    Lespron Robles Mdel C; Molina Méndez J
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-185-93. PubMed ID: 18938724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
    Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
    Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function.
    Koster A; Pasic M; Bauer M; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Jan; 69(1):37-41. PubMed ID: 10654482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass.
    Khuri SF; Valeri CR; Loscalzo J; Weinstein MJ; Birjiniuk V; Healey NA; MacGregor H; Doursounian M; Zolkewitz MA
    Ann Thorac Surg; 1995 Oct; 60(4):1008-14. PubMed ID: 7574939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
    Sakai M; Ohteki H; Narita Y; Naitoh K; Natsuaki M; Itoh T
    Cardiovasc Surg; 1999 Mar; 7(2):187-94. PubMed ID: 10353669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review.
    Boer C; Meesters MI; Veerhoek D; Vonk ABA
    Br J Anaesth; 2018 May; 120(5):914-927. PubMed ID: 29661409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
    Kuitunen AH; Heikkilä LJ; Salmenperä MT
    Ann Thorac Surg; 1997 Feb; 63(2):438-44. PubMed ID: 9033316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant monitoring techniques in a heparin-induced thrombocytopenia patient undergoing cardiopulmonary bypass using bivalirudin anticoagulant.
    Baker T; Chan R; Hill F
    J Extra Corpor Technol; 2004 Dec; 36(4):371-4. PubMed ID: 15679282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
    Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia.
    Clayton SB; Acsell JR; Crumbley AJ; Uber WE
    Ann Thorac Surg; 2004 Dec; 78(6):2167-9. PubMed ID: 15561064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure.
    Prifti E; Bonacchi M; Leacche M; Miraldi F
    Eur J Cardiothorac Surg; 2000 Jun; 17(6):760-2. PubMed ID: 10856875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.